1.
患者的临床特征
Clinical characteristics of patients
| Category | n (%) |
| EGFR: epidermal growth factor receptor; ALK: anaplasticlymphoma kinase. | |
| Age (yr) | |
| ≥60 | 18 (29.0) |
| < 60 | 44 (71.0) |
| Gender | |
| Male | 21 (33.9) |
| Female | 41 (66.1) |
| Smoking status | |
| Ever | 56 (90.3) |
| Never | 6 (9.7) |
| EGFR mutation | |
| Positive | 30 (48.4) |
| Negative | 32 (51.6) |
| ALK rearrangement | |
| Positive | 13 (21.0) |
| Negative | 49 (79.0) |
| Driver mutation | |
| Yes | 43 (69.4) |
| No | 19 (30.6) |
| Brain metastases | |
| Yes | 28 (45.2) |
| No | 34 (54.8) |
| Bone metastases | |
| Yes | 25 (40.3) |
| No | 37 (59.7) |
| Cycles of bevacizumab | |
| ≤6 | 32 (51.6) |
| > 6 | 30 (48.4) |
| Platinum-based regimens | |
| Yes | 24 (38.7) |
| No | 38 (61.3) |